@article{c0e8c1eeb3234418a0671b314360bfc9,
title = "Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome",
abstract = "MECP2 loss-of-function mutations cause Rett syndrome, a neurodevelopmental disorder resulting from a disrupted brain transcriptome. How these transcriptional defects are decoded into a disease proteome remains unknown. We studied the proteome of Rett cerebrospinal fluid (CSF) to identify consensus Rett proteome and ontologies shared across three species. Rett CSF proteomes enriched proteins annotated to HDL lipoproteins, complement, mitochondria, citrate/pyruvate metabolism, synapse compartments, and the neurosecretory protein VGF. We used shared Rett ontologies to select analytes for orthogonal quantification and functional validation. VGF and ontologically selected CSF proteins had genotypic discriminatory capacity as determined by receiver operating characteristic analysis in Mecp2-/y and Mecp2−/+. Differentially expressed CSF proteins distinguished Rett from a related neurodevelopmental disorder, CDKL5 deficiency disorder. We propose that Mecp2 mutant CSF proteomes and ontologies inform putative mechanisms and biomarkers of disease. We suggest that Rett syndrome results from synapse and metabolism dysfunction.",
keywords = "Clinical neuroscience, Disease, Pathophysiology, Proteomics",
author = "Zlatic, {Stephanie A.} and Duc Duong and Gadalla, {Kamal K.E.} and Brenda Murage and Lingyan Ping and Ruth Shah and Fink, {James J.} and Omar Khwaja and Swanson, {Lindsay C.} and Mustafa Sahin and Sruti Rayaprolu and Prateek Kumar and Srikant Rangaraju and Adrian Bird and Daniel Tarquinio and Randall Carpenter and Stuart Cobb and Victor Faundez",
note = "Funding Information: VF was funded by the Rett Syndrome Research Trust, the Loulou Foundation, and NIH 1RF1AG060285. S Rangaraju was partly funded by the NIH (5R01NS114130). S Rayaprolu was partly supported by the NIH (F32 AG064862).SC was funded by the Rett Syndrome Research Trust and Simons Initiative for the Developing Brain. JJF was funded by the Rett Syndrome Research Trust. VF is grateful for mitochondria provided by Maria Olga Gonzalez. Conceptualization: S.A.Z. R.C. D.T. and V.F.; Methodology: S.A.Z. D.D. L.P. K.K.E.G. B.M. S.R. P.K. and S.R; Investigation: S.A.Z. D.D. L.P. K.K.E.G. and B.M; Visualization: V.F. Writing – original draft: V.F. and S.A.Z.; Writing – review and editing: V.F. S.A.Z. R.C. A.B. and D.T.; Reagents: R.S. L.K. L.C.S. M.H. A.B. and J.J.F. Mustafa Sahin reports grant support from Novartis, Biogen, Astellas, Aeovian, Bridgebio, and Aucta. He has served on Scientific Advisory Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar Therapeutics and Alkermes. James J. Fink is an employee of Q-State Biosciences. VF is a member of the iScience editorial board. Funding Information: VF was funded by the Rett Syndrome Research Trust , the Loulou Foundation , and NIH 1RF1AG060285 . S Rangaraju was partly funded by the NIH ( 5R01NS114130 ). S Rayaprolu was partly supported by the NIH ( F32 AG064862 ).SC was funded by the Rett Syndrome Research Trust and Simons Initiative for the Developing Brain . JJF was funded by the Rett Syndrome Research Trust . VF is grateful for mitochondria provided by Maria Olga Gonzalez. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = sep,
day = "16",
doi = "10.1016/j.isci.2022.104966",
language = "English",
volume = "25",
journal = "iScience",
issn = "2589-0042",
publisher = "Cell Press",
number = "9",
}